Earnings Releases·Nov 3, 2026, 8:22 AM ET

Compass Pathways — Third Quarter 2026 Earnings Summary

Net loss narrowed significantly to $9.8 million for the quarter (vs. $137.7 million in 2025) and $172.4 million for the nine months (vs. $194.0 million in 2025), driven largely by a $40.8 million non-cash gain on warrant liabilities; R&D expenses declined while SG&A rose to $33.0 million due to commercial preparation costs.
Cash reserves increased to $444.0 million as of September 30, 2026, providing sufficient funding to cover operating and capital expenditures through 2028, despite total debt rising to $51.0 million.
Final NDA submission is nearing completion with a filing expected within two weeks, targeting a first-half 2027 launch subject to FDA approval, with potential for accelerated review via the National Priority Voucher.
Clinical data from two positive Phase 3 trials and 52-week open-label studies reinforce COMP360's rapid onset, durability, and added benefit from a 25 mg dose, supporting a "launch-ready" status for the TRD market.